<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sredob</journal-id><journal-title-group><journal-title xml:lang="ru">Здоровье населения и среда обитания – ЗНиСО</journal-title><trans-title-group xml:lang="en"><trans-title>Public Health and Life Environment – PH&amp;LE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-5238</issn><issn pub-type="epub">2619-0788</issn><publisher><publisher-name>ФБУЗ ФЦГиЭ Роспотребнадзора</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35627/2219-5238/2021-337-4-74-78</article-id><article-id custom-type="elpub" pub-id-type="custom">sredob-505</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Роль растворимых молекул CD25, CD38, CD95 в формировании иммуносупрессии при цитомегаловирусной инфекции</article-title><trans-title-group xml:lang="en"><trans-title>The Role of Soluble Molecules CD25, CD38, and CD95 in the Development of Immunosuppression in Cytomegalovirus Infection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2449-7213</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новиков Виктор Владимирович – д.б.н., профессор, заведующий лабораторией иммунохимии; профессор кафедры молекулярной биологии и иммунологии</p><p>ул. Малая Ямская, д. 71, г. Нижний Новгород, 603950</p><p>пр. Гагарина, д. 23, г. Нижний Новгород, 603950</p></bio><bio xml:lang="en"><p>Viktor V. Novikov, D.Biol.Sc., Professor, Head of the Laboratory of Immunochemistry</p><p>71 Malaya Yamskaya Street, Nizhny Novgorod, 603950</p><p>23 Gagarin Avenue, Nizhny Novgorod, 603950</p></bio><email xlink:type="simple">mbre@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6983-6883</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравченко</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchenko</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кравченко Галина Анатольевна – к.б.н, доцент; доцент кафедры молекулярной биологии и иммунологии</p><p>пр. Гагарина, д. 23, г. Нижний Новгород, 603950</p></bio><bio xml:lang="en"><p>Galina A. Kravchenko, Candidate of Biological Sciences, Associate Professor, Department of Molecular Biology and Immunology</p><p>23 Gagarin Avenue, Nizhny Novgorod, 603950</p></bio><email xlink:type="simple">kravchukgala@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3828-9316</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Собчак</surname><given-names>Д. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Sobchak</surname><given-names>D. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Собчак Девора Михайловна – д.м.н., профессор; профессор кафедры инфекционных болезней</p><p>пл. Минина и Пожарского, д. 10/1, г. Нижний Новгород, 603005</p></bio><bio xml:lang="en"><p>Devora M. Sobchak, D.M.Sc., Professor, Department of Infectious Diseases</p><p>10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005</p></bio><email xlink:type="simple">sobchak_devora@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7049-6935</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новиков Дмитрий Викторович – к.б.н., доцент; вед. науч. сотр. </p><p>ул. Малая Ямская, д. 71, г. Нижний Новгород, 603950</p></bio><bio xml:lang="en"><p>Dmitry V. Novikov, Candidate of Biological Sciences, Associate Professor</p><p>71 Malaya Yamskaya Street, Nizhny Novgorod, 603950</p></bio><email xlink:type="simple">novikov.dv75@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2727-2888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шумилова</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shumilova</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шумилова Светлана Викторовна – к.б.н., ст. науч. сотр. </p><p>пр. Гагарина, д. 23, г. Нижний Новгород, 603950</p></bio><bio xml:lang="en"><p>Svetlana V. Shumilova, Candidate of Biological Sciences, Senior Researcher, Institute of Biology and Biomedicine</p><p>23 Gagarin Avenue, Nizhny Novgorod, 603950</p></bio><email xlink:type="simple">swetlana.shumilova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФБУН «Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной» Роспотребнадзора; ФГАОУ ВО «Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского» Минобрнауки России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology; National Research Lobachevsky State University of Nizhny Novgorod</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского» Минобрнауки России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Lobachevsky State University of Nizhny Novgorod</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volga Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФБУН «Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной» Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2021</year></pub-date><volume>0</volume><issue>4</issue><fpage>74</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Новиков В.В., Кравченко Г.А., Собчак Д.М., Новиков Д.В., Шумилова С.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Новиков В.В., Кравченко Г.А., Собчак Д.М., Новиков Д.В., Шумилова С.В.</copyright-holder><copyright-holder xml:lang="en">Novikov V.V., Kravchenko G.A., Sobchak D.M., Novikov D.V., Shumilova S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://zniso.fcgie.ru/jour/article/view/505">https://zniso.fcgie.ru/jour/article/view/505</self-uri><abstract><p>Введение. Инфицирование цитомегаловирусом (ЦМВ), принадлежащим к бета-герпесвирусам, широко распространено в человеческой популяции и приближается у пожилых лиц к 100 %. Обычно инфекция протекает в латентной форме, но при развитии иммуносупрессии способна к реактивации. Механизмы реактивации до конца не изучены. Целью настоящей работы явилось исследование роли растворимых молекул CD25, CD38, CD95 в формировании иммуносупрессии при цитомегаловирусной инфекции. Материалы и методы. В работе использовали образцы сыворотки крови больных с цитомегаловирусной инфекцией в стадии реактивации, подтвержденной c помощью клинических и лабораторных данных. Больные проходили лечение в Инфекционной клинической больнице № 2 г. Нижнего Новгорода. Сывороточное содержание суммарных и олигомерных растворимых молекул CD25, CD38 и CD95 определяли иммуноферментным методом с помощью моноклональных антител и поликлональных антител, направленных против белков мононуклеарных клеток периферической крови человека. Результаты регистрировали спектрофотометрически и оценивали, переводя единицы оптической плотности в условные единицы (U/ml). Результаты. Показано, что у больных с реактивацией цитомегаловирусной инфекции происходит повышение сывороточного содержания суммарной и олигомерной фракций растворимых молекул CD25, CD38 и CD95. Если сывороточное содержание суммарной и олигомерной фракций молекул CD25 и CD38 повышается в одинаковой степени, то для олигомерной фракции молекул CD95 обнаружено более выраженное повышение в сравнении с суммарной фракцией. Полученные данные позволяют предположить наличие при цитомегаловирусной инфекции механизма супрессии иммунного ответа, связанного с инициацией апоптоза эффекторных Т-лимфоцитов с участием олигомерной формы молекул CD95. Заключение. Изменения в содержании и структурно-функциональном состоянии растворимых дифференцировочных молекул CD25, CD38 и CD95 свидетельствуют об их участии в механизмах иммуносупрессии у больных с цитомегаловирусной инфекцией.</p></abstract><trans-abstract xml:lang="en"><p>Introduction: Cytomegalovirus (CMV) infection is a common beta-herpesvirus infection widely spread in the human population. The proportion of infected population increases with age and approaches 100 % in elderly people. The infection is usually latent but is capable of reactivation when immunosuppression develops. The mechanisms of reactivation are not fully understood. The objective of our study was to evaluate the role of soluble molecules CD25, CD38, CD95 in the development of immunosuppression in CMV infection. Materials and methods: We used 18 serum samples from cases of CMV disease in the stage of reactivation, all confirmed by clinical and laboratory data. The patients received treatment in Nizhny Novgorod Infectious Disease Hospital No. 2. The serum content of the total and oligomeric soluble molecules CD25, CD38, and CD95 was identified by ELISA using monoclonal and polyclonal antibodies against human peripheral blood mononuclear cell proteins. The results were recorded spectrophotometrically and evaluated by converting optical density units to conventional units (U/mL). Results: We established an increase in the serum content of total and oligomeric fractions of soluble molecules CD25, CD38, and CD95 in the cases of CMV disease. While the serum content of the total and oligomeric fractions of molecules CD25 and CD38 increased equally, the oligomeric fraction of molecules СD95 demonstrated a more pronounced increase compared to the total fraction of these molecules. Our findings suggest the immune response suppression mechanism associated with initiation of apoptosis of effector T lymphocytes involving oligomeric form of molecules CD95. Conclusion: Changes in the content, structural and functional state of soluble differentiating molecules CD25, CD38, and CD95 indicate their involvement in immunosuppression mechanisms in patients with CMV infection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>цитомегаловирсная инфекция</kwd><kwd>иммуносупрессия</kwd><kwd>растворимые молекулы CD25</kwd><kwd>CD38</kwd><kwd>CD95.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytomegalovirus infection</kwd><kwd>immunosuppression</kwd><kwd>soluble molecules CD25</kwd><kwd>CD38</kwd><kwd>and CD95</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was carried out within the framework of the Sectoral Research Program “Research and Development with the Purpose of Ensuring Sanitary and Epidemiological Wellbeing and Infectious Disease Prevention in the Russian Federation”.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ziemann M, Thiele T. Transfusion-transmitted CMV infection – current knowledge and future perspectives. Transfus Med. 2017; 27(4):238–248. doi: 10.1111/tme.12437</mixed-citation><mixed-citation xml:lang="en">Ziemann M, Thiele T. Transfusion-transmitted CMV infection – current knowledge and future perspectives. Transfus Med. 2017; 27(4):238–248. doi: 10.1111/tme.12437</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(4). doi: 10.1128/microbiolspec.DMIH20022-2015</mixed-citation><mixed-citation xml:lang="en">Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(4). doi: 10.1128/microbiolspec.DMIH20022-2015</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Silva JM, Pinheiro-Silva R, Dhyani A, Pontes GS. Cytomegalovirus and Epstein-Barr infections: prevalence and impact on patients with hematological diseases. Biomed Res Int. 2020;2020:1627824. doi: 10.1155/2020/1627824</mixed-citation><mixed-citation xml:lang="en">Silva JM, Pinheiro-Silva R, Dhyani A, Pontes GS. Cytomegalovirus and Epstein-Barr infections: prevalence and impact on patients with hematological diseases. Biomed Res Int. 2020;2020:1627824. doi: 10.1155/2020/1627824</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vauloup-Fellous C, Berth M, Heskia F, Dugua JM, Grangeot-Keros L. Re-evaluation of the VIDAS (®) cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation. J Clin Virol. 2013;56(2):118–23. doi: 10.1016/j.jcv.2012.10.017</mixed-citation><mixed-citation xml:lang="en">Vauloup-Fellous C, Berth M, Heskia F, Dugua JM, Grangeot-Keros L. Re-evaluation of the VIDAS (®) cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation. J Clin Virol. 2013;56(2):118–23. doi: 10.1016/j.jcv.2012.10.017</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kabani N, Ross SA. Congenital cytomegalovirus infection. J Infect Dis. 2020;5:221(Suppl 1):S9–S14. doi: 10.1093/infdis/jiz446</mixed-citation><mixed-citation xml:lang="en">Kabani N, Ross SA. Congenital cytomegalovirus infection. J Infect Dis. 2020;5:221(Suppl 1):S9–S14. doi: 10.1093/infdis/jiz446</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lindemann M, Korth J, Sun M, Xu S, Struve C, Werner K, et al. The cytomegalovirus-specific IL-21 ELISpot correlates with allograft function of kidney transplant recipients. Int J Mol Sci. 2018;19(12):3945. doi: 10.3390/ijms19123945</mixed-citation><mixed-citation xml:lang="en">Lindemann M, Korth J, Sun M, Xu S, Struve C, Werner K, et al. The cytomegalovirus-specific IL-21 ELISpot correlates with allograft function of kidney transplant recipients. Int J Mol Sci. 2018;19(12):3945. doi: 10.3390/ijms19123945</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020;223(3):330–349. doi: 10.1016/j.ajog.2020.02.018</mixed-citation><mixed-citation xml:lang="en">Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020;223(3):330–349. doi: 10.1016/j.ajog.2020.02.018</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Afshari A, Yaghobi R, Karimi MH, Darbouy M, Azarpira N, Geramizadeh B, et al. IL-17 mRNA expression and cytomegalovirus infection in liver transplant patients. Exp Clin Transplant. 2015;13(Suppl 1):83–89.</mixed-citation><mixed-citation xml:lang="en">Afshari A, Yaghobi R, Karimi MH, Darbouy M, Azarpira N, Geramizadeh B, et al. IL-17 mRNA expression and cytomegalovirus infection in liver transplant patients. Exp Clin Transplant. 2015;13(Suppl 1):83–89.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dornieden T, Wilde B, Korth J, Werner K, Horn PA, Witzke O, et al. Enhancement of cytomegalovirusspecific cytokine production after modulation of the costimulation in kidney transplant patients. J Immunol Res. 2019;2019:3926175. doi: 10.1155/2019/3926175</mixed-citation><mixed-citation xml:lang="en">Dornieden T, Wilde B, Korth J, Werner K, Horn PA, Witzke O, et al. Enhancement of cytomegalovirusspecific cytokine production after modulation of the costimulation in kidney transplant patients. J Immunol Res. 2019;2019:3926175. doi: 10.1155/2019/3926175</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367–77. doi: 10.1038/nri.2016.38</mixed-citation><mixed-citation xml:lang="en">Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367–77. doi: 10.1038/nri.2016.38</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев М.Ю., Шолкина М.Н., Новиков Д.В., Шумилова С.В., Новиков В.В., Караулов А.В. Сывороточное содержание растворимых молекул СD25 и CD95 у ожоговых больных // Вестник Российской академии медицинских наук. 2017. Т. 72. № 4. С. 276–281.</mixed-citation><mixed-citation xml:lang="en">Lebedev MJu, Sholkina MN, Novikov DV, Shumilova SV, Novikov VV, Karaulov AV. Soluble CD25 and CD95 molecules level at burns. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2017;72(4):276–281. (In Russian). doi: 10.15690/vramn772</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ma A, Zhang L, Ye X, Chen J, Yu J, Zhuang L, et al. High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19. Front Immunol. 2021;12:626235. doi: 10.3389/fimmu.2021.626235</mixed-citation><mixed-citation xml:lang="en">Ma A, Zhang L, Ye X, Chen J, Yu J, Zhuang L, et al. High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19. Front Immunol. 2021;12:626235. doi: 10.3389/fimmu.2021.626235</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Vanmaris RMM, Rijkers GT. Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122–129. doi: 10.36141/svdld.v34i2.5369</mixed-citation><mixed-citation xml:lang="en">Vanmaris RMM, Rijkers GT. Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122–129. doi: 10.36141/svdld.v34i2.5369</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sun HL, Ma CJ, Du XF, Yang S-Y, Lv X, Zhao H, et al. Soluble IL-2Rα correlates with imbalances of Th1/ Th2 and Tc1/Tc2 cells in patients with acute brucellosis. Infect Dis Poverty. 2020;9(1):92. doi: 10.1186/s40249-02000699-y</mixed-citation><mixed-citation xml:lang="en">Sun HL, Ma CJ, Du XF, Yang S-Y, Lv X, Zhao H, et al. Soluble IL-2Rα correlates with imbalances of Th1/ Th2 and Tc1/Tc2 cells in patients with acute brucellosis. Infect Dis Poverty. 2020;9(1):92. doi: 10.1186/s40249-02000699-y</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marcante R, Cavedon G. Soluble CD4, CD8 and interleukin-2 receptor levels in patients with acute cytomegalovirus mononucleosis syndrome. Allergol Immunopathol (Madr). 1991;19(3):99–102.</mixed-citation><mixed-citation xml:lang="en">Marcante R, Cavedon G. Soluble CD4, CD8 and interleukin-2 receptor levels in patients with acute cytomegalovirus mononucleosis syndrome. Allergol Immunopathol (Madr). 1991;19(3):99–102.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zedtwitz-Liebenstein K, Diab-Elschahaw M, Frass M. Human cytomegalovirus infection in nonimmunocompromised patients: a retrospective analysis and review of the literature. Intervirology. 2016;59(3):159–162. doi: 10.1159/000454772</mixed-citation><mixed-citation xml:lang="en">Zedtwitz-Liebenstein K, Diab-Elschahaw M, Frass M. Human cytomegalovirus infection in nonimmunocompromised patients: a retrospective analysis and review of the literature. Intervirology. 2016;59(3):159–162. doi: 10.1159/000454772</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Da Cunha T, Wu GY. Cytomegalovirus hepatitis in immunocompetent and immunocompromised hosts. J Clin Transl Hepatol. 2021;9(1):106–115. doi: 10.14218/JCTH.2020.00088</mixed-citation><mixed-citation xml:lang="en">Da Cunha T, Wu GY. Cytomegalovirus hepatitis in immunocompetent and immunocompromised hosts. J Clin Transl Hepatol. 2021;9(1):106–115. doi: 10.14218/JCTH.2020.00088</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Komura T, Kagaya T, Takayama H, Yanagi M, Yoshio T, Sugimoto S, et al. Clinical features and dynamics of T cells-related markers in immunocompetent patients with cytomegalovirus hepatitis. Can J Gastroenterol Hepatol. 2020;2020:8874620. doi: 10.1155/2020/8874620</mixed-citation><mixed-citation xml:lang="en">Komura T, Kagaya T, Takayama H, Yanagi M, Yoshio T, Sugimoto S, et al. Clinical features and dynamics of T cells-related markers in immunocompetent patients with cytomegalovirus hepatitis. Can J Gastroenterol Hepatol. 2020;2020:8874620. doi: 10.1155/2020/8874620</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков В.В., Макарова Е.В., Шумилова С.В. Красногорова Н.В., Варварина Г.Н. Растворимые дифференцировочные молекулы как биомаркеры при ХОБЛ. Аллергология и иммунология. 2017. Т. 18. № 3. С. 157–160.</mixed-citation><mixed-citation xml:lang="en">Novikov VV, Makarova EV, Shumilova SV, Krasnogorova NV, Varvarina GN. Soluble differentiation molecules as biomarkers in COPD. Allergologiya i Immunologiya. 2017;18(3):157–160. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков В.В., Евсегнеева И.В. Новые дифференцировочные антигены человека, утвержденные на VII Международном Воркшопе // Российский биотерапевтический журнал. 2003. Т. 2. № 3. С. 3–6.</mixed-citation><mixed-citation xml:lang="en">Novikov VV, Evsegneeva IV. New human differentiation antigens adopted at the VII International Workshop. Rossiyskiy Bioterapevticheskiy Zhurnal. 2003; 2(3):3–6. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lebedev MJu, Egorova NI, Sholkina MN, Vilkov SA, Baryshnikov AJu, Novikov VV. Serum levels of different forms of soluble CD38 antigen in burned patients. Burns. 2004;30(6):552–556. doi: 10.1016/j.burns.2004.01.029</mixed-citation><mixed-citation xml:lang="en">Lebedev MJu, Egorova NI, Sholkina MN, Vilkov SA, Baryshnikov AJu, Novikov VV. Serum levels of different forms of soluble CD38 antigen in burned patients. Burns. 2004;30(6):552–556. doi: 10.1016/j.burns.2004.01.029</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Голенков А.К., Митина Т.А., Новиков В.В., Тагиров О.Т., Королева В.В., Крыжанов М.А. и др. Клиническое значение растворимых молекул адгезии (sCD50 ICAM 3), апоптоза (sCD95) и sHLA класса I при лимфопролиферативных заболеваниях // Российский биотерапевтический журнал. 2002. Т. 1. № 1. С. 60–64.</mixed-citation><mixed-citation xml:lang="en">Golenkov AK, Mitina TA, Novikov VV, Tagirov OT, Koroleva VV, Kryzhanov MA, et al. [Clinical significance of soluble adhesion molecules (sCD50 ICAM-3), apoptosis (sCD95) and sHLA class I in lymphoproliferative diseases.] Rossiyskiy Bioterapevticheskiy Zhurnal. 2002;1(1):60–64. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Vincent FB, Kandane-Rathnayake R, Koelmeyer R, et al. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1):e000375. doi: 10.1136/lupus-2019-000375</mixed-citation><mixed-citation xml:lang="en">Vincent FB, Kandane-Rathnayake R, Koelmeyer R, et al. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1):e000375. doi: 10.1136/lupus-2019-000375</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ptitsina YuS, Bornyakova LA, Baryshnikov AYu, Martynova TG, Kryzhanova MA, Novikov VV. A soluble form of FAS/APO-1(CD95) antigen in the serum of viral hepatitis patients. International Journal on Immunorehabilitation. 1999;(14):110.</mixed-citation><mixed-citation xml:lang="en">Ptitsina YuS, Bornyakova LA, Baryshnikov AYu, Martynova TG, Kryzhanova MA, Novikov VV. A soluble form of FAS/APO-1(CD95) antigen in the serum of viral hepatitis patients. International Journal on Immunorehabilitation. 1999;(14):110.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Liu Y, Han R, Li Q, Yao Z, Niu W, et al. Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation. J Gastroenterol Hepatol. 2010;25(1):138–42. doi: 10.1111/j.14401746.2009.05966.x</mixed-citation><mixed-citation xml:lang="en">Wang Y, Liu Y, Han R, Li Q, Yao Z, Niu W, et al. Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation. J Gastroenterol Hepatol. 2010;25(1):138–42. doi: 10.1111/j.14401746.2009.05966.x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
